Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III, randomized, open‐label, controlled trial

AIM: To compare the efficacy and safety of LY2963016 insulin glargine (LY IGlar) with insulin glargine (Lantus; IGlar) combined with oral antihyperglycaemic medications (OAMs) in insulin‐naive Chinese patients with type 2 diabetes (T2D). MATERIALS AND METHODS: In this phase III, open‐label trial, ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Wenhuan, Chen, Wei, Jiang, Shan, Du, Liying, Zhu, Dalong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361736/
https://www.ncbi.nlm.nih.gov/pubmed/33783964
http://dx.doi.org/10.1111/dom.14392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361736/
https://www.ncbi.nlm.nih.gov/pubmed/33783964
http://dx.doi.org/10.1111/dom.14392

Ejemplares similares